Debating the Role of ALP Normalization in PBC: Curbside Consults Podcast

03/24/25 • 21 min

In this podcast, expert faculty, Dr Stuart Gordon and Dr Nancy Reau, use an illustrative patient case to explore the roles of ALP and other biochemical markers in PBC management, and explain what to expect from treatment. Topics covered include:

How baseline ALP can affect ALP normalization after second-line treatment with elafibranor and seladelpar
Potential outcomes if ALP normalization cannot be achieved
The importance of managing fatigue, pruritus, and sleep disturbances independently of the biochemical response

Presenters:

Stuart C. Gordon, MD
Professor of Medicine
Wayne State University School of Medicine
Director, Division of Hepatology
Henry Ford Health
Detroit, Michigan

Nancy Reau, MD
Professor of Medicine
Richard B. Capps Chair of Hepatology
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Rush University Medical Center
Chicago, Illinois

To learn more about PBC management, check out our program, Curbside Consults: Expert Insights on Challenges in PBC Management.

How baseline ALP can affect ALP normalization after second-line treatment with elafibranor and seladelpar
Potential outcomes if ALP normalization cannot be achieved
The importance of managing fatigue, pruritus, and sleep disturbances independently of the biochemical response

Presenters:

Stuart C. Gordon, MD
Professor of Medicine
Wayne State University School of Medicine
Director, Division of Hepatology
Henry Ford Health
Detroit, Michigan

Nancy Reau, MD
Professor of Medicine
Richard B. Capps Chair of Hepatology
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Rush University Medical Center
Chicago, Illinois

To learn more about PBC management, check out our program, Curbside Consults: Expert Insights on Challenges in PBC Management.

Previous Episode

Managing PBC Therapy for Patients With Cirrhosis: Curbside Consults Podcast

In this podcast, expert faculty, Dr Stuart Gordon and Dr Nancy Reau discuss an illustrative patient case to demonstrate how they individualize primary biliary cholangitis (PBC) therapy for patients with cirrhosis. Topics covered include:

AASLD guideline recommendations for second-line therapy for PBC
Considerations when using newer agents for second-line treatment of PBC in patients with cirrhosis: elafibranor and seladelpar

Presenters:

Stuart C. Gordon, MD
Professor of Medicine
Wayne State University School of Medicine
Director, Division of Hepatology
Henry Ford Health
Detroit, Michigan

Nancy Reau, MD
Professor of Medicine
Richard B. Capps Chair of Hepatology
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Rush University Medical Center
Chicago, Illinois

To learn more about PBC management, check out our program,
Curbside Consults: Expert Insights on Challenges in PBC Management.

Next Episode

Partnering With Patients for PBC Care: Actionable Strategies for HCPs

In this episode, Dr Gideon Hirschfield meets with patient advocate Jess Schnur to discuss challenges related to the diagnosis and management of primary biliary cholangitis (PBC) to provide actionable strategies for healthcare professionals to incorporate into patient care, including:

Disease concerns and frequently asked questions from a patient perspective
Managing symptoms
Treatment options and supportive care
Importance of awareness and education

Presenters:
Gideon Hirschfield, MA, MB BChir, FRCP, PhD
Lily and Terry Horner Chair in Autoimmune Liver Disease Research
Professor, Division of Gastroenterology and Hepatology
University of Toronto
Director, The Autoimmune and Rare Liver Disease Programme
Director, Francis Family Liver Clinic
Toronto General Hospital, University Health Network
Ontario, Canada

Jess N. Schnur, BSN-RN
National PBC Patient Advocate
American Liver Foundation
Donation Support Services Coordinator
Lifeline of Ohio
Columbus, Ohio

To learn more, see the program Hear Me: Patient Perspectives on PBC